Form D · Pharmaceuticals
BioIntervene, Inc.
Brisbane, CA · CIK 0001771460
Offering snapshot reported Jun 23, 2021 · SEC filing
- Reported sold
- $5.64M Offering amount: $5.64M
- Investors reported
- Not reported Form D · investor count
- Minimum accepted
- Not reported Reported outside-investor minimum
- First sale
- Not reported As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 23, 2021 | Initial | $5,642,585 | No comparison | Not reported | SEC filing |
| Mar 25, 2019 | Initial | $3,125,000 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- Not reported
- Duration over one year
- Not reported
- Business combination
- Not reported
- Sales commissions
- Not reported
- Finders' fees
- Not reported
- Form D file number
- 021-403933
Source: Form D, filed Jun 23, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Gary J. Bennett | Director |
| David Bredt | Director |
| Ed Hurwitz | Director |
| Gary Patou | Director |
| Daniela Salvemini | Director |
| Simon Tate | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
C/O Mpm Capital 2000 Sierra Point Parkway, Suite 701
Brisbane, CA, 94005
Brisbane, CA, 94005